gern buy idea with stop shown in the graphgern buy idea with stop shown in the graph
we must keep the stop as shown in the graph
Key facts today
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.2730 USD
−174.57 M USD
76.99 M USD
597.84 M
About Geron Corporation
Sector
Industry
CEO
Dawn Carter Bir
Website
Headquarters
Foster City
Founded
1990
FIGI
BBG00JRQS0J0
Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Foster City, CA.
Is $GERN a stock for "Strong Holders"?Or is it just another stock whose value will be wiped out in the next few quarters, and the company will simply lose its listing on the Nasdaq?
Investors are likely to get an answer to this question today, before the market opens, when NASDAQ:GERN reports its quarterly earnings.
The company has
geron corporationpure price action , i see this asset making the last push to the down before going higher
Long GERN @4.43 Oversold in a strong recent uptrend. Will hold each lot until it is both overbought AND profitable. No stops for me. Had a dizzying 40% drawdown back in September '23 and held 14 lots at the bottom of that.
In the end, though, all 14 (and the next 13) turned a profit. The indicator and exit str
GERN - PDUFA Data Release on 16/06/2024Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blo
GERON Corporation Bullish momentum
Title:
GERON Corporation: Bullish Momentum
Overview:
🌟 Hello Traders,
GERON Corporation is currently exhibiting bullish momentum, indicating potential opportunities for traders in the market.
NASDAQ:GERN
Key Points:
- GERON Corporation is experiencing strong bullish momentum, with
Geron's Imetelstat Receives FDA Advisors' BackingGeron Corporation's ( NASDAQ:GERN ) blood disorder drug, Imetelstat, has received a crucial vote of confidence from advisers to the U.S. Food and Drug Administration (FDA). Despite initial concerns raised by the agency's staff regarding data clarity and safety issues, the advisory panel overwhelming
GERON Stock Chart Fibonacci Analysis 022724Trading Idea
1) Find a FIBO slingshot
2) Check FIBO 61.80% level
3) Entry Point > 2.2/61.80%
Chart time frame : B
A) 15 min(1W-3M)
B) 1 hr(3M-6M)
C) 4 hr(6M-1year)
D) 1 day(1-3years)
Stock progress : B
A) Keep rising over 61.80% resistance
B) 61.80% resistance
C) Hit the bottom
D) Hit the top
GERN - long - Catalyst playGeron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's leading drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a
BUY GERON CORP. (GERN)Shares of Geron have been on the retail trader’s radar following a series of news and industry catalysts. The late-stage biopharmaceutical company specializes in developing treatments for hematologic malignancies. At the beginning of the year, the company announced positive top-line results from its
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Related stocks
Frequently Asked Questions
The current price of 0IV3 is 1.6195 USD — it has decreased by −0.63% in the past 24 hours. Watch GERON CORP COM STK USD0.001 stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange GERON CORP COM STK USD0.001 stocks are traded under the ticker 0IV3.
0IV3 stock has fallen by −0.59% compared to the previous week, the month change is a −30.00% fall, over the last year GERON CORP COM STK USD0.001 has showed a −51.30% decrease.
We've gathered analysts' opinions on GERON CORP COM STK USD0.001 future price: according to them, 0IV3 price has a max estimate of 7.00 USD and a min estimate of 2.00 USD. Watch 0IV3 chart and read a more detailed GERON CORP COM STK USD0.001 stock forecast: see what analysts think of GERON CORP COM STK USD0.001 and suggest that you do with its stocks.
0IV3 reached its all-time high on Mar 27, 2018 with the price of 5.9800 USD, and its all-time low was 0.9960 USD and was reached on Feb 4, 2022. View more price dynamics on 0IV3 chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
0IV3 stock is 3.74% volatile and has beta coefficient of 1.31. Track GERON CORP COM STK USD0.001 stock price on the chart and check out the list of the most volatile stocks — is GERON CORP COM STK USD0.001 there?
Today GERON CORP COM STK USD0.001 has the market capitalization of 1.05 B, it has increased by 8.75% over the last week.
Yes, you can track GERON CORP COM STK USD0.001 financials in yearly and quarterly reports right on TradingView.
GERON CORP COM STK USD0.001 is going to release the next earnings report on May 12, 2025. Keep track of upcoming events with our Earnings Calendar.
0IV3 earnings for the last quarter are −0.04 USD per share, whereas the estimation was −0.02 USD resulting in a −62.53% surprise. The estimated earnings for the next quarter are −0.03 USD per share. See more details about GERON CORP COM STK USD0.001 earnings.
GERON CORP COM STK USD0.001 revenue for the last quarter amounts to 47.54 M USD, despite the estimated figure of 61.84 M USD. In the next quarter, revenue is expected to reach 50.46 M USD.
0IV3 net income for the last quarter is −25.35 M USD, while the quarter before that showed −26.45 M USD of net income which accounts for 4.14% change. Track more GERON CORP COM STK USD0.001 financial stats to get the full picture.
No, 0IV3 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Mar 29, 2025, the company has 229 employees. See our rating of the largest employees — is GERON CORP COM STK USD0.001 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. GERON CORP COM STK USD0.001 EBITDA is −172.51 M USD, and current EBITDA margin is −224.06%. See more stats in GERON CORP COM STK USD0.001 financial statements.
Like other stocks, 0IV3 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade GERON CORP COM STK USD0.001 stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So GERON CORP COM STK USD0.001 technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating GERON CORP COM STK USD0.001 stock shows the sell signal. See more of GERON CORP COM STK USD0.001 technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.